Bradmer Pharmaceuticals Inc. (TSE:GLX – Free Report) – Stock analysts at Atb Cap Markets reduced their FY2025 EPS estimates for shares of Bradmer Pharmaceuticals in a research note issued to investors on Sunday, March 30th. Atb Cap Markets analyst M. Toner now forecasts that the company will post earnings of ($0.92) per share for the year, down from their previous forecast of $1.51. Atb Cap Markets also issued estimates for Bradmer Pharmaceuticals’ FY2026 earnings at $0.73 EPS.
Separately, Cantor Fitzgerald upgraded shares of Bradmer Pharmaceuticals to a “strong-buy” rating in a report on Tuesday, February 25th.
Bradmer Pharmaceuticals Price Performance
Featured Stories
- Five stocks we like better than Bradmer Pharmaceuticals
- Consumer Discretionary Stocks Explained
- D-Wave: Multiple Use Cases Emerge Following Quantum Supremacy
- What Are Trending Stocks? Trending Stocks Explained
- Amazon Falls Back to a Key Support Line: Here’s How to Play It
- What is the NASDAQ Stock Exchange?
- Buffett Trims Equities, But Still Keeps Buying This Stock
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
